Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company's products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company's product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company's products consist of instruments, consumables and systems that are made up of various individual products.
Industry, Sector and Symbol:
- Sector: Computer and Technology
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:HBIO
- CUSIP: 41690610
- Web: www.harvardbioscience.com
Capitalization:- Market Cap: $88.28 million
- Outstanding Shares: 34,618,000
Average Prices:- 50 Day Moving Avg: $2.55
- 200 Day Moving Avg: $2.65
- 52 Week Range: $2.25 - $3.30
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 53.00
- P/E Growth: 1.67
Sales & Book Value:- Annual Revenue: $101.71 million
- Price / Sales: 0.90
- Book Value: $2.10 per share
- Price / Book: 1.26
Profitability:- EBIDTA: $2.53 million
- Net Margins: -4.66%
- Return on Equity: 2.41%
- Return on Assets: 1.62%
Debt:- Debt-to-Equity Ratio: 0.15%
- Current Ratio: 3.21%
- Quick Ratio: 1.77%
Misc:- Average Volume: 56,967 shs.
- Beta: 1.06
- Short Ratio: 8.54
Frequently Asked Questions for Harvard Bioscience (NASDAQ:HBIO)
What is Harvard Bioscience's stock symbol?
Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."
How were Harvard Bioscience's earnings last quarter?
Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its earnings results on Thursday, July, 28th. The company reported $0.03 EPS for the quarter, meeting the Zacks' consensus estimate of $0.03. The company earned $26.10 million during the quarter, compared to analysts' expectations of $26.60 million. Harvard Bioscience had a negative net margin of 4.66% and a positive return on equity of 2.41%. View Harvard Bioscience's Earnings History.
Where is Harvard Bioscience's stock going? Where will Harvard Bioscience's stock price be in 2017?
2 brokerages have issued 1 year price targets for Harvard Bioscience's stock. Their predictions range from $5.50 to $6.00. On average, they expect Harvard Bioscience's share price to reach $5.75 in the next year. View Analyst Ratings for Harvard Bioscience.
Who are some of Harvard Bioscience's key competitors?
Some companies that are related to Harvard Bioscience include Alliance HealthCare Services (AIQ), Cytosorbents Corporation (CTSO), Viveve Medical (VIVE), FULGENT GENETIC (FLGT), IRIDEX Corporation (IRIX), Cogentix Medical (CGNT), Neovasc (NVCN), Edap Tms S.A. (EDAP), Digirad Corporation (DRAD), Biolase (BIOL), Electromed (ELMD), Presbia PLC (LENS), EnteroMedics (ETRM), Xtant Medical Holdings (XTNT), Advanced Oncotherapy PLC (AVO), Dextera Surgical (DXTR), Sphere Medical Holding PLC (SPHR) and PhotoMedex (PHMD).
Who are Harvard Bioscience's key executives?
Harvard Bioscience's management team includes the folowing people:
- James W. Green, Chairman of the Board
- Jeffrey A Duchemin, President, Chief Executive Officer, Director
- Robert E Gagnon, Chief Financial Officer
- Yong Sun, Vice President - Strategic Marketing and Business Development
- David M. Green, Director
- Neal J. Harte, Independent Director
- John F. Kennedy, Independent Director
- Bertrand Loy, Independent Director
- George Uveges, Independent Director
Who owns Harvard Bioscience stock?
Harvard Bioscience's stock is owned by many different of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (2.12%) and ICM Asset Management Inc. WA (0.32%). Company insiders that own Harvard Bioscience stock include David Green, Earl R Lewis, George Uveges, James W Green, Jeffrey Duchemin, John F Kennedy and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.
Who sold Harvard Bioscience stock? Who is selling Harvard Bioscience stock?
Harvard Bioscience's stock was sold by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA and Acadian Asset Management LLC. Company insiders that have sold Harvard Bioscience stock in the last year include David Green and Earl R Lewis. View Insider Buying and Selling for Harvard Bioscience.
How do I buy Harvard Bioscience stock?
Shares of Harvard Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Harvard Bioscience's stock price today?
One share of Harvard Bioscience stock can currently be purchased for approximately $2.65.
MarketBeat Community Rating for Harvard Bioscience (NASDAQ HBIO)MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Harvard Bioscience (NASDAQ:HBIO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $5.75 (116.98% upside) |
Analysts' Ratings History for Harvard Bioscience (NASDAQ:HBIO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/21/2016 | Benchmark Co. | Set Price Target | Buy | $6.00 | N/A |  |
| 11/17/2016 | Singular Research | Initiated Coverage | Buy | $5.50 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Harvard Bioscience (NASDAQ:HBIO)Earnings History by Quarter for Harvard Bioscience (NASDAQ HBIO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/9/2017 | Q4 2016 | $0.04 | $0.01 | $26.90 million | $26.42 million | View | Listen | |
| 10/27/2016 | Q3 | $0.01 | $0.01 | $26.00 million | $25.01 million | View | Listen | |
| 7/28/2016 | Q2 | $0.03 | $0.03 | $26.60 million | $26.10 million | View | Listen | |
| 5/12/2016 | Q1 | $0.02 | $0.05 | $26.00 million | $27.00 million | View | Listen | |
| 4/29/2016 | Q4 | $0.03 | $0.03 | | $28.37 million | View | N/A | |
| 10/29/2015 | Q315 | $0.05 | $0.03 | $27.01 million | $25.70 million | View | Listen | |
| 7/30/2015 | Q215 | $0.04 | $0.05 | $26.60 million | $28.80 million | View | Listen | |
| 4/30/2015 | Q414 | $0.05 | $0.01 | $27.15 million | $25.80 million | View | Listen | |
| 2/26/2015 | Q314 | $0.09 | $0.08 | $29.30 million | $30.40 million | View | N/A | |
| 10/30/2014 | Q214 | $0.06 | $0.05 | $25.46 million | $25.40 million | View | N/A | |
| 7/31/2014 | Q2 | $0.05 | $0.05 | $26.00 million | $26.96 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.02) | $0.05 | $28.20 million | $27.90 million | View | N/A | |
| 10/31/2013 | Q313 | $0.01 | $0.05 | $26.10 million | $25.10 million | View | N/A | |
| 5/2/2013 | Q1 2013 | | $0.08 | $28.30 million | $26.10 million | View | N/A | |
| 11/1/2012 | Q312 | | $0.08 | $26.40 million | $26.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Harvard Bioscience (NASDAQ:HBIO)Current Year EPS Consensus Estimate: $0.06 EPS
Next Year EPS Consensus Estimate: $0.05 EPS
Dividend History for Harvard Bioscience (NASDAQ:HBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Harvard Bioscience (NASDAQ:HBIO)Insider Ownership Percentage: 8.80%
Institutional Ownership Percentage: 61.98%
Insider Trades by Quarter for Harvard Bioscience (NASDAQ:HBIO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/12/2017 | Jeffrey Duchemin | CEO | Buy | 22,000 | $2.76 | $60,720.00 | |
| 6/8/2017 | James W. Green | Director | Buy | 7,712 | $2.55 | $19,665.60 | |
| 5/26/2017 | Robert E. Gagnon | CFO | Buy | 1,000 | $2.33 | $2,330.00 | |
| 5/25/2017 | Earl R. Lewis | Director | Buy | 12,238 | $2.35 | $28,759.30 | |
| 5/24/2017 | Earl R. Lewis | Director | Buy | 10,000 | $2.38 | $23,800.00 | |
| 2/7/2017 | David Green | Director | Sell | 3,239 | $3.25 | $10,526.75 | |
| 2/6/2017 | David Green | Director | Sell | 1,288 | $3.25 | $4,186.00 | |
| 12/6/2016 | Earl R. Lewis | Director | Sell | 23,088 | $2.42 | $55,872.96 | |
| 11/3/2016 | Jeffrey Duchemin | CEO | Buy | 15,000 | $2.42 | $36,300.00 | |
| 11/3/2016 | Robert E. Gagnon | CFO | Buy | 25,000 | $2.34 | $58,500.00 | |
| 12/10/2015 | Jeffrey Duchemin | CEO | Buy | 10,000 | $3.37 | $33,700.00 | |
| 12/3/2015 | George Uveges | Director | Buy | 3,000 | $3.32 | $9,960.00 | |
| 11/9/2015 | Robert E Gagnon | CFO | Buy | 3,000 | $3.08 | $9,240.00 | |
| 9/2/2015 | Jeffrey Duchemin | CEO | Buy | 2,000 | $4.41 | $8,820.00 | |
| 9/1/2015 | John F Kennedy | Director | Buy | 2,000 | $4.33 | $8,660.00 | |
| 7/17/2015 | David Green | Director | Sell | 17,103 | $5.26 | $89,961.78 | |
| 7/14/2015 | David Green | Director | Sell | 51,597 | $5.28 | $272,432.16 | |
| 4/23/2015 | David Green | Director | Sell | 118,500 | $6.03 | $714,555.00 | |
| 4/22/2015 | David Green | Director | Sell | 123,997 | $6.23 | $772,501.31 | |
| 4/17/2015 | David Green | Director | Sell | 42,503 | $6.55 | $278,394.65 | |
| 4/14/2015 | David Green | Director | Sell | 80,168 | $6.61 | $529,910.48 | |
| 2/9/2015 | David Green | Director | Sell | 48,712 | $5.25 | $255,738.00 | |
| 12/30/2014 | David Green | Director | Sell | 16,173 | $5.25 | $84,908.25 | |
| 12/29/2014 | David Green | Director | Sell | 100,167 | $5.25 | $525,876.75 | |
| 12/22/2014 | David Green | Director | Sell | 80,202 | $5.02 | $402,614.04 | |
| 11/19/2014 | David Green | Director | Sell | 10,000 | $4.95 | $49,500.00 | |
| 10/31/2014 | David Green | Director | Sell | 117,654 | $4.97 | $584,740.38 | |
| 6/16/2014 | Robert E Gagnon | CFO | Buy | 5,000 | $3.86 | $19,300.00 | |
| 5/29/2014 | Neal J Harte | Director | Sell | 12,317 | $3.82 | $47,050.94 | |
| 4/9/2014 | David Green | Director | Sell | 27,540 | $4.47 | $123,103.80 | |
| 4/8/2014 | David Green | Director | Sell | 66,090 | $4.48 | $296,083.20 | |
| 4/3/2014 | David Green | Director | Sell | 63,501 | $4.63 | $294,009.63 | |
| 8/27/2013 | Chane Graziano | Major Shareholder | Buy | 60,000 | $5.00 | $300,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Harvard Bioscience (NASDAQ:HBIO)
Latest Headlines for Harvard Bioscience (NASDAQ:HBIO)
| Source: |
|
| Date | Headline |
|---|
 | Harvard Bioscience, Inc. (HBIO) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 21 at 9:56 PM |
 | Harvard Bioscience Schedules Second Quarter 2017 Conference Call for July 27 at 4:30 PM ET
finance.yahoo.com - July 18 at 9:19 PM |
 | Harvard Bioscience Schedules Second Quarter 2017 Conference Call for July 27 at 4:30 PM ET
feeds.benzinga.com - July 18 at 5:57 PM |
| Zacks Investment Research Lowers Harvard Bioscience, Inc. (NASDAQ:HBIO) to Hold
www.americanbankingnews.com - July 16 at 12:59 PM |
| Harvard Bioscience, Inc. (NASDAQ:HBIO) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - July 12 at 10:56 PM |
 | Biopharmaceutical Companies to Remain the Largest End-user of Chromatography Resins Globally
www.prnewswire.com - July 11 at 5:26 AM |
| ETFs with exposure to Harvard Bioscience, Inc. : July 5, 2017
finance.yahoo.com - July 5 at 7:58 PM |
| Insider Buying: Harvard Bioscience, Inc. (HBIO) CEO Acquires 22,000 Shares of Stock
www.americanbankingnews.com - June 13 at 8:38 PM |
| James W. Green Acquires 7,712 Shares of Harvard Bioscience, Inc. (HBIO) Stock
www.americanbankingnews.com - June 9 at 8:44 PM |
| ETFs with exposure to Harvard Bioscience, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 6:37 PM |
 | Harvard Bioscience (HBIO) Names James Green as Chairman
www.streetinsider.com - June 7 at 10:12 PM |
| Harvard Bioscience Elects James Green as Chairman of Board of Directors
finance.yahoo.com - June 7 at 5:09 PM |
| ValuEngine Downgrades Harvard Bioscience, Inc. (HBIO) to Sell
www.americanbankingnews.com - June 4 at 1:04 PM |
| Earl R. Lewis Buys 12,238 Shares of Harvard Bioscience, Inc. (HBIO) Stock
www.americanbankingnews.com - May 31 at 7:28 AM |
| Harvard Bioscience, Inc. (HBIO) Director Earl R. Lewis Buys 10,000 Shares
www.americanbankingnews.com - May 25 at 8:28 PM |
| ETFs with exposure to Harvard Bioscience, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 6:12 PM |
| Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 12:48 PM |
| Harvard Bioscience (HBIO) Earns Daily News Sentiment Rating of 0.57
www.americanbankingnews.com - May 3 at 10:30 AM |
| Harvard Bioscience (HBIO) Earning Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 30 at 10:51 AM |
| Harvard Bioscience, Inc. (HBIO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 29 at 1:13 AM |
| Edited Transcript of HBIO earnings conference call or presentation 27-Apr-17 8:30pm GMT
finance.yahoo.com - April 28 at 6:36 PM |
 | Harvard Bioscience reports 1Q loss
marketbeat.com - April 27 at 5:45 PM |
| Investor Network: Harvard Bioscience, Inc. to Host Earnings Call
finance.yahoo.com - April 27 at 3:33 PM |
| Somewhat Positive Media Coverage Very Likely to Impact Harvard Bioscience (HBIO) Share Price
www.americanbankingnews.com - April 26 at 9:24 PM |
| Harvard Bioscience Schedules First Quarter 2017 Conference Call for April 27 at 4:30 PM ET
finance.yahoo.com - April 19 at 8:43 PM |
| Harvard Bioscience (HBIO) Earning Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 13 at 11:16 AM |
| ETFs with exposure to Harvard Bioscience, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:30 PM |
| HARVARD BIOSCIENCE INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 17 at 5:51 PM |
 | Harvard Bioscience's (HBIO) CEO Jeffrey Duchemin on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 10 at 10:17 AM |
| Edited Transcript of HBIO earnings conference call or presentation 9-Mar-17 9:30pm GMT
finance.yahoo.com - March 10 at 10:17 AM |
| Q4 2016 Harvard Bioscience Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 9 at 6:01 PM |
 | Harvard Bioscience Reports Fourth Quarter and Year-End 2016 Results and 2017 Financial Guidance
us.rd.yahoo.com - March 9 at 6:01 PM |
| Harvard Bioscience, Inc. (HBIO) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 8 at 9:19 AM |
| Harvard Bioscience Schedules Fourth Quarter 2016 Conference Call for March 9 at 4:30 PM ET
finance.yahoo.com - February 23 at 5:37 PM |
| Harvard Bioscience, Inc. (HBIO) Presents At Singular Research "Uncovered Values & Special Situation Web Call"
seekingalpha.com - December 20 at 10:54 AM |
| Coverage initiated on Harvard Biosci by Singular Research
finance.yahoo.com - November 17 at 4:54 PM |
| HARVARD BIOSCIENCE INC Financials
finance.yahoo.com - November 10 at 4:46 PM |
| Edited Transcript of HBIO earnings conference call or presentation 27-Oct-16 8:30pm GMT
finance.yahoo.com - October 29 at 8:17 AM |
| Harvard Bioscience Inc Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - October 27 at 5:26 PM |
| Q3 2016 Harvard Bioscience Inc Earnings Release - After Market Close
biz.yahoo.com - October 27 at 10:07 AM |
| Harvard Bioscience (HBIO): Moving Average Crossover Alert
finance.yahoo.com - August 29 at 5:16 PM |
 | EXCLUSIVE: UW president lays out vision for Global Innovation Exchange
www.bizjournals.com - August 17 at 5:36 PM |
| 7:30 am Harvard Bioscience reports Q2; guides FY16
finance.yahoo.com - July 28 at 7:30 AM |
| Harvard Bioscience Schedules Second Quarter 2016 Conference Call for July 28 at 8:30 AM ET
finance.yahoo.com - July 18 at 4:30 PM |
| HARVARD BIOSCIENCE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - June 27 at 4:16 PM |
| HARVARD BIOSCIENCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
biz.yahoo.com - May 27 at 4:11 PM |
| Edited Transcript of HBIO earnings conference call or presentation 12-May-16 12:30pm GMT
finance.yahoo.com - May 12 at 10:50 AM |
| Q4 2015 and Q1 2016 Harvard Bioscience Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - May 12 at 8:30 AM |
| Q1 2016 Harvard Bioscience Inc Earnings Release - Before Market Open
biz.yahoo.com - May 12 at 7:07 AM |
| HARVARD BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
biz.yahoo.com - May 12 at 6:24 AM |
Harvard Bioscience (HBIO) Chart for Thursday, July, 27, 2017
